S5182 Viral Sabotage: HBV Reactivation in the Shadow of HIV

Introduction: This is a case report of a 57-year-old gentleman who presented to a tertiary medical center in acute liver failure due to reactivation of hepatitis B virus (HBV) after not taking his Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) for 4 months. This case highlights the importance of adhering to antiretroviral therapy (ART) in the setting co-infection with HBV and HIV and the consequences when not doing so. It also highlights successful medical management of acute liver failure without consulting a liver transplant center. Hepatitis reactivation typically occurs in patients who are incompletely treated or immunocompromised due to chemotherapy or other immunosuppressive agents. Acute reactivation can present with symptoms of acute liver failure if severe. It is more rare for reactivation to occur in patients who were fully treated and “resolved”, with negative HBsAg. Case Description/Methods: We present a case of a 74-year-old man with history of well controlled HIV on ART, treated hepatitis B and C, and epilepsy who presented with increased seizure frequency with unrelenting post-ictal-like state of decreased arousal, confusion, and falls. Initial labs revealed aspartate aminotransferase >5,000, alanine aminotransferase 5,612, Total Bilirubin 6.1, alkaline phosphatase 144, Platelets 101, international normalized ratio 2.1, Ammonia 130. Patient was admitted to the general medicine floor at a tertiary medical center for medical management of acute liver failure. Reactivation of HBV was identified with seroconversion to positive HBsAg from negative 2 years prior, positive HBcAg, negative HBeAg, and viral load 79 million. Four-month ART non-compliance, unknown to care-givers, was identified by prescription fill history and evidenced by increased HIV viral load (49,000) and decreased CD4 count (344) compared to 4 months prior. Treatment with Biktarvy and lactulose was initiated, and within 6 days, hepatic function recovered and mental status improved to baseline. Discussion: HIV medication has antiviral effects on HBV, when HIV antiretroviral therapy is stopped HBV can become reactivated. This case is unique in it's presentation of seizures in the setting of acute reactivation of HBV, timely initiation of antiviral treatment in acute hepatitis with successful recovery despite poor prognosis, and management options for acute liver failure at a tertiary medical center.

Authors

Publication Details

Journal
The American Journal of Gastroenterology
Published
2025-10-01
DOI
https://doi.org/10.14309/01.ajg.0001148188.28439.b5
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

S5182 Viral Sabotage: HBV Reactivation in the Shadow of HIV

Elizabeth Armstrong, James R. Miller, Julian Lippert, Zachary Mitchell
The American Journal of Gastroenterology
Hepatitis B Virus Studies
article

S5182 Viral Sabotage: HBV Reactivation in the Shadow of HIV

Elizabeth Armstrong, James R. Miller, Julian Lippert, Zachary Mitchell
article en

Abstract

Introduction: This is a case report of a 57-year-old gentleman who presented to a tertiary medical center in acute liver failure due to reactivation of hepatitis B virus (HBV) after not taking his Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) for 4 months. This case highlights the importance of adhering to antiretroviral therapy (ART) in the setting co-infection with HBV and HIV and the consequences when not doing so. It also highlights successful medical management of acute liver failure without consulting a liver transplant center. Hepatitis reactivation typically occurs in patients who are incompletely treated or immunocompromised due to chemotherapy or other immunosuppressive agents. Acute reactivation can present with symptoms of acute liver failure if severe. It is more rare for reactivation to occur in patients who were fully treated and “resolved”, with negative HBsAg. Case Description/Methods: We present a case of a 74-year-old man with history of well controlled HIV on ART, treated hepatitis B and C, and epilepsy who presented with increased seizure frequency with unrelenting post-ictal-like state of decreased arousal, confusion, and falls. Initial labs revealed aspartate aminotransferase >5,000, alanine aminotransferase 5,612, Total Bilirubin 6.1, alkaline phosphatase 144, Platelets 101, international normalized ratio 2.1, Ammonia 130. Patient was admitted to the general medicine floor at a tertiary medical center for medical management of acute liver failure. Reactivation of HBV was identified with seroconversion to positive HBsAg from negative 2 years prior, positive HBcAg, negative HBeAg, and viral load 79 million. Four-month ART non-compliance, unknown to care-givers, was identified by prescription fill history and evidenced by increased HIV viral load (49,000) and decreased CD4 count (344) compared to 4 months prior. Treatment with Biktarvy and lactulose was initiated, and within 6 days, hepatic function recovered and mental status improved to baseline. Discussion: HIV medication has antiviral effects on HBV, when HIV antiretroviral therapy is stopped HBV can become reactivated. This case is unique in it's presentation of seizures in the setting of acute reactivation of HBV, timely initiation of antiviral treatment in acute hepatitis with successful recovery despite poor prognosis, and management options for acute liver failure at a tertiary medical center.

The American Journal of GastroenterologyVol. 120(10S2)
Openalex Percentile: Top 49%
Hepatitis B Virus Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.